GlassScriptPhysician profile
Adam C Harrison
NPI 1922329267
$3,675.89
in general payments reported to CMS, 2019-2025
34 companies · $1,797 in 2025
The $1,797 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $305 · 2021: $474 · 2022: $287 · 2023: $261 · 2024: $311 · 2025: $1,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,491 · Travel and Lodging: $836 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,490.80 |
| Travel and Lodging | $835.99 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,563.04 | 2021-2025 | Minimed 780g |
| Pfizer INC. | $417.40 | 2019-2025 | |
| Abbvie INC. | $355.04 | 2019-2024 | |
| Astellas Pharma US INC | $277.63 | 2019-2024 | Veozah |
| Novo Nordisk INC | $146.62 | 2021-2024 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $112.74 | 2019-2022 | |
| Corcept Therapeutics | $65.85 | 2021-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.01 | 2019-2025 | Jardiance |
| Mannkind Corporation | $62.73 | 2025 | |
| Sanofi-Aventis U.S. LLC | $55.38 | 2019-2025 | |
| Lilly USA, LLC | $49.75 | 2021-2025 | Mounjaro |
| Indivior INC. | $36.03 | 2019-2025 | Sublocade |
| Novartis Pharmaceuticals Corporation | $34.54 | 2022-2024 | |
| Tandem Diabetes Care, INC. | $34.11 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Eisai INC. | $31.16 | 2021-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicomp INC | $30.90 | 2024 | Telepatch Cardiac Monitor |
| Ironwood Pharmaceuticals, INC | $26.20 | 2020 | |
| Horizon Therapeutics Plc | $25.41 | 2022 | |
| Csl Behring | $23.74 | 2021 | |
| Biogen, INC. | $22.40 | 2025 | Leqembi |
| Xeris Pharmaceuticals, INC. | $21.88 | 2025 | Recorlev |
| Braintree Laboratories, INC. | $21.87 | 2023 | Sutab |
| Sequel Med Tech, LLC | $21.82 | 2025 | Twiist |
| Inspire Medical Systems, INC. | $21.16 | 2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.79 | 2022 | |
| Boston Scientific Corporation | $19.39 | 2024 | |
| Radius Health, INC. | $18.20 | 2019 | |
| Dexcom, INC. | $17.80 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $17.53 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.76 | 2023 | Austedo |
| Allergan, INC. | $11.87 | 2020 | |
| Amgen INC. | $11.79 | 2020 | |
| Amarin Pharma, INC. | $11.25 | 2020 | |
| Glaxosmithkline, LLC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.